1140TiP Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab.

Authors :: Janssen, J.C.
van Dijk, B.
de Joode, K.
Aarts, M.
Van den Berkmortel, F.
Blank, C.U.
Boers-Sonderen, M.
Van Den Eertwegh, F.
de Groot, J.W.
Jalving, M.
Joosse, A.
Huismans, A.
Kapiteijn, E.
Naipal, K.A.T.
Piersma, D.
Rikhof, B.
Vreugdenhil, G.
Westgeest, H.M.
Mulder, E.E.A.P.
Van der Veldt, A.A.M.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS748-S748. 1p.
Publication Year :: 2024

Full Text Access

Tools